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A B S T R A C T   
Calreticulin, the major Ca2+ buffer of the endoplasmic reticulum plays an important role in the choice of fate by embryonic stem cells. Using the embryoid body 
method of organogenesis, we showed impaired osteogenesis in crt−/− cells vis-à-vis calreticulin-containing osteogenic WT cells. In the non-osteogenic crt−/− cells, c- 
Src- a non-receptor tyrosine kinase- was activated and its inhibition rescued osteogenesis. Most importantly, we demonstrated that calreticulin-containing cells had 
lower c-Src kinase activity, and this was accomplished via the Ca2+-homeostatic function of calreticulin. Specifically, lowering cytosolic [Ca2+] in calreticulin- 
containing osteogenic WT cells with BAPTA-AM, activated c-Src and impaired osteogenic differentiation. Conversely, increasing cytosolic [Ca2+] in crt−/− cells with 
ionomycin deactivated c-Src kinase and restored osteogenesis. The immediate effector of calreticulin, the Ser/Thr phosphatase calcineurin, was less active in crt−/− 
cells, however, its activity was rescued upon inhibition of c-Src activity by small molecule inhibitors. Finally, we showed that higher activity of calcineurin correlated 
with increased level of nuclear Runx2, a transcription factor that is the master regulator of osteogenesis. Collectively, our work has identified a novel pathway 
involving calreticulin regulated Ca2+ signalling via c-Src in osteogenic differentiation of embryonic stem cells.  
1. Introduction 
Calreticulin (CRT) is an endoplasmic reticulum (ER)-residing protein 
that regulates the intracellular Ca2+ ([Ca2+]i) homeostasis via its high 
Ca2+ storage capacity (Nishida, 1983; Toyoshima et al., 1986; Michalak 
et al., 2009). Calreticulin plays an important role in embryonic stem (ES) 
cell differentiation and development (Groenendyk and Michalak, 2014; 
Karimzadeh and Opas, 2017; Papp et al., 2009; Szabo et al., 2009; Pilquil 
et al., 2020). While calreticulin deficiency is lethal in utero due to im-
paired cardiac development, over-expression of constitutively active calci-
neurin (CaN; a Ca2 + -regulated Ser/Thr phosphatase) in the hearts of 
calreticulin deficient mice is able to rescue them from embryonic lethality, 
making it possible to study live, calreticulin deficient animals (Guo, 2002; 
Lynch and Michalak, 2003). As such, calcineurin has been shown to be one 
of calreticulin’s effectors via calreticulin’s intracellular Ca2+ homeostatic 
functions (Lynch and Michalak, 2003; Lynch, 2005; Lynch et al., 2006). In 
addition, gain- and loss-of-function experiments indicated that higher cal-
cineurin expression is positively correlated with osteoblastic differentiation 
and bone formation in mice, although the potential mechanisms have not 
been fully elucidated (Pilquil et al., 2020; Sun, 2005; Tomita et al., 2002; 
Winslow, 2006). Together these findings underscore the significance of the 
calreticulin/Ca2+/calcineurin signalling axis in osteogenic differentiation. 
We recently demonstrated that calreticulin regulates ES cell (ESC) 
osteogenic differentiation, where loss of calreticulin reduces osteogenic 
differentiation (Pilquil et al., 2020). Src family kinases play crucial roles 
in regulating cellular adhesion, growth, migration, and differentiation 
(Parsons and Parsons, 2004). c-Srchas been shown to increase the rate of 
bone resorption in mice (Soriano et al., 1991) and to decrease osteoblast 
differentiation in vitro (Cornelese-ten Velde et al., 1988; D'Souza et al., 
1988). It has been shown that the loss or underexpression of calreticulin 
increases total tyrosine phosphorylation levels (Khatami et al., 1986). c- 
Src was shown to be highly activated by loss of calreticulin in fibroblasts 
(Papp et al., 2007, 2008). However, while the inhibitory role of c-Src in 
osteogenesis has been studied (D'Souza et al., 1988), the effects of c-Src 
on osteoblast differentiation downstream of calreticulin is unclear. 
In the present study, we demonstrate that in the absence of calreti-
culin, osteogenic differentiation of calreticulin-deficient (crt−/−) mouse 
ESCs (mESCs) is impaired compared to wild type (WT) mESCs. c-Src 
activity is increased in crt−/− mESCs and, importantly, c-Src activity is 
shown to be regulated by [Ca2+]I, such that lowering of [Ca2+]i results 
in increased c-Src activity. The absence of calreticulin inhibits the ac-
tivity of calcineurin and activates c-Src, which results in inhibition of the 
nuclear translocation of the master osteogenic transcription factor, runt- 
domain related transcription factor 2 (Runx2). This suggests a novel 
mechanism in which c-Src regulates mESCs osteogenic differentiation via 
the effects on Runx2 subcellular trafficking, downstream of calreticulin. 
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2. Materials and methods 
2.1. Cell culture 
Mouse embryonic stem cell lines used in the study (WT, crt −/− and 
crt−/−+Crt, and crt−/−+CaN) were maintained in LIF containing 
medium. Osteogenic differentiation was performed via the hanging 
drop method using an optimized protocol developed in our laboratory 
(Yu et al., 2016). 250 cells per 25 µL drops were placed on the lids of 
tissue culture dishes for 3 days. The medium consisted of high glucose 
Dulbecco modified Eagle’s medium with sodium pyruvate and L-glu-
tamine, 20% FBS, nonessential amino acids, and β-mercaptoethanol. 
After 3 days in hanging drop, ES cell aggregates called EBs were then 
floated in differentiation medium containing 0.1 µM retinoic acid for 
2 days. On day 5, the EBs were plated in tissue culture dishes coated 
with 0.1% gelatin in PBS. Retinoic acid was added in the media for the 
entire duration of the EBs in floating stage. On day 6, the differentiation 
medium was supplemented with 50 µg/mL ascorbic acid and 10 mM β- 
Fig. 1. c-Src activity is increased in the absence of calreticulin expression in WT mESCs. (A) Effect of calreticulin on expression of osteogenic markers mRNA. 
Total RNA was extracted from day 21 nodules differentiated from WT, crt−/−, and crt−/−+Crt ESCs and subjected to qPCR analysis using Runx2, SP7, and Ibsp 
primer pairs. mRNA expression was calculated by normalizing ct values to L32 housekeeping gene. Fold change was calculated when values were normalized against 
corresponding crt−/− values. Data expressed as means  ±  SD, and n of minimum 3, and two-way ANOVA analysis among WT, crt−/−, and crt-/−+CRT ESCs results: 
F = 154.9, p  <  0.0001. Bonferroni post hoc analysis as indicated: *p  <  0.05, **p  <  0.01. (B) Mineralization of mESCs in the absence and presence of calreticulin 
expression assessed by von Kossa staining. Mineralized deposits of Day 21 nodules differentiated from WT, crt−/−, and crt−/−+Crt ESCs using osteogenic protocol 
were stained by von Kossa method. (C) c-Src activity in mESCs in the presence and absence of calreticulin. p-Y416-c-Src levels and levels of total c-Src were examined 
in immunoblots. GAPDH served as loading control. (D) Quantification of western blot analysis. p-Y416-c-Src band densities were quantified using ImageJ. 
Normalized values to corresponding total c-Src representing the mean ( ± SD) were graphed and subjected to Kruskal-Wallis test (p  <  0.0001). Multiple com-
parisons were performed where each comparison stands individually using Dunnett’s test and indicated as *p  <  0.05 and *** < 0.005. 
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glycerophosphate for commitment to the osteogenic lineage. Dex-
amethasone (100 nM) was added on day 10 to further enrich cells of the 
osteogenic lineage. The medium was changed every 2 days for the 
entire 21 days of differentiation. 
2.2. Inhibition assays 
Ionomycin (Sigma-Aldrich, Catalog No. I3909) and BAPTA-AM 
(Sigma-Aldrich, Catalog No. A1076) treatments were performed. To 
chelate cytosolic Ca2+, floating EBs were incubated with 0.1 µM 
(caption on next page) 
Z. Alvandi, et al.   Stem Cell Research 48 (2020) 101972
3
BAPTA-AM for 30 min each day at days 3–5 of differentiation. To 
increase cytosolic Ca2+, the EBs were incubated with 1 µM iono-
mycin for 2 h each day in the same manner. For inhibition of calci-
neurin, floating EBs were incubated with 1 µg/ml cyclosporin-A (for 
2 h). c-Src inhibitor PP2 (Calbiochem, Catalog No. 529573), SrcI1 
(Sigma, Catalog No. S2075), and negative control PP3 (Calbiochem, 
Catalog No. 529574) were applied based on survey by Bain et al. 
(Bain et al., 2003) at 10uM and 1uM each day between day 3 to 5, 
respectively. 
2.3. Calcineurin activity assay 
Calcineurin activity assay was carried out as previously described 
(Fruman et al., 1992). Briefly, a peptide corresponding to the regulatory 
domain of protein kinase A was used as the substrate in an in vitro 
dephosphorylation assay. Cells (1.0 × 106) were lysed in 50 ul of hy-
potonic lysis buffer and 20 ul of lysate was added to 32P-labeled RII- 
peptide (300 pmols). The reaction was carried out for 15 min at 30°C 
and number of pmols released phosphate was calculated. Activity of 
calcineurin was expressed in pmols of phosphate released per minute 
per mg of total protein. 
2.4. Mineral deposition assays 
Differentiated day 21 nodules were examined for the presence of 
mineral deposits using von Kossa and Arsenazo III staining as per-
formed in previous studies (Bellows et al., 1986). Briefly, for von Kossa 
staining, cells were rinsed three times with PBS, fixed in 10% neutral 
formalin buffer for 2 hr, then washed 3 times with distilled water. 
Nodules were then stained with 2.5% silver nitrate solution for 30 min. 
After, they were washed 3 times with distilled water and were ex-
amined for presence of mineralization. For Arsenazo III staining, the 
amount of Ca2+ in the matrix was measured using Arsenazo III (Sigma) 
staining method as previously described (Michaylova and Ilkova, 
1971). 
2.5. Real-time PCR analysis 
The Qiagen RNeasy Mini Kit was used to extract total RNA from 
day 21 nodules according to the manufacturer’s instructions. 4 µg of 
RNA was reverse transcribed to cDNA using Superscript II (Invitrogen) 
in a total reaction volume of 48 µL. Real-time PCR analysis was per-
formed in Bio-Rad’s CFX384 Touch detection system. The primer se-
quences that were designed and used are as follows: for L32, forward 
primer 5′-CATGGCTGCCCTTCGGCCTC-3′ and reverse primer 5′-CAT 
TCTCTTCGCTGCGTAGCC-3′;for RUNX2, forward primer 5′- CCTCTG 
ACTTCTGCCTCTGG-3′ and reverse primer 5′-TAAAGGTGGCTGGGTA 
GTGC-3′; 
for SP7, forward primer 5′-AAGTCCCACACAGCAGCTG-3′ and re-
verse primer 5′- AGCCGAGCTGCCAGAGTTTG-3′; and for Ibsp, forward 
primer 5′- AACAATCCGTGCCACTCA-3′ and reverse primer 5′-GGAGG 
GGGCTTCACTGAT-3′. 
2.6. SDS-PAGE and western blot analysis 
Cells were collected in a lysis buffer containing 50 mM Tris-HCl, 
pH 8.0, 120 mM NaCl, and 0.5% NP-40. 30 ug lysates per lane were 
separated by SDS-PAGE and transferred to nitrocellulose membrane. 
The following primary antibodies were used: anti-c-Src (Cell 
Signaling, Catalog No. 2108), anti-p-c-Src-Y416 (Cell Signaling, 
Catalog No.2101S), anti- Runx2 (Cell Signaling, Catalog No.8486S), 
and anti-GAPDH (Cell Signaling, Catalog No.2118S) antibodies. The 
secondary antibody used was Goat polyclonal Secondary Antibody 
to Rabbit IgG - H&L (HRP) (Abcam, Catalog No. ab6721). 
Immunoreactive bands were detected using the DNR 
MicroChem chemiluminescence camera system (DNR Bio-Imaging 
Systems) and were quantified using ImageJ (developed by Wayne 
Rasband, NIH, https://imagej.nih.gov/ij/) where indicated. 
2.7. Immunofluorescence staining 
Day 21 nodules on coverslips were rinsed 3 times with PBS, and 
fixed in 3.7% formaldehyde for 15 min. After washing in PBS, the cells 
were permeabilized with 0.1% Triton X-100 in buffered containing 
100 mM 1,4- piperazinediethanesulfonic acid, 1 mM EGTA, and 4% 
(wt/vol) polyethylene glycol 8000 (pH 6.9) for 2 min. Nodules were 
then washed by PBS and were incubated with 1:50 dilution of anti- 
Runx2 (Abcam, Catalog No. ab76956) at 4°C overnight. After washing 
in PBS (3 times for 5 min), the cells were stained with the secondary 
antibody diluted 1:1000 for 1hr at room temperature. For nuclear 
staining, 500 nM PI solution was added to cover the nodules for 5 min. 
After final rinsing in PBS, the slides were mounted in fluorescent 
mounting medium (Dako, Catalog No. S3023). A confocal fluorescence 
microscope (MRC 600; Bio-Rad Laboratories) equipped with a 60/1.40 
plan Apochromatic oil immersion objective (Nikon) and krypton-argon 
laser was used for fluorescence imaging. COSMOS software (Bio-Rad 
Laboratories) was used for image acquisition. 
2.8. Image and Statistical analysis 
Mander’s and Pearson’s coefficients were calculated using ImageJ 
freeware [https://imagej.nih.gov/ij/] from a minimum of three random 
fields of view. Manders’ overlap coefficient measures positions and in-
tensities of fluorescence of pixels in each colour channel. It returns 
values ranging from 1 to 0, thus showing full colocalization or no co-
localization, respectively. Pearson's correlation coefficient is not 
Fig. 2. Inhibition of c-Src activity in crt−/− cells improved osteogenic differentiation. (A) c-Src inhibition and its effect on osteogenic markers mRNA ex-
pression. Total RNA was extracted from day 21 nodules differentiated from WT, crt−/−, and crt−/−+Crt ESCs under osteogenic protocol and analysed by qPCR using 
Runx2, SP7, and Ibsp primer pairs. mRNA expression was calculated by normalizing values to L32 housekeeping gene. Fold change was calculated when values were 
normalized to their corresponding DMSO condition. Values representing the mean ( ± SD) of triplicates were graphed and subjected to two-way ANOVA; F = 196.3, 
p  <  0.0001. Bonferroni post hoc analysis as indicated: *p  <  0.05, **p  <  0.01. (B) c-Src inhibition and its effect on mineralization of non-osteogenic crt−/− mESCs 
assessed by Arsenazo III staining. Day 21 nodules of crt−/− with the indicated treatments were stained by Arsenazo III method. The absorbance of the Ca-Arsenazo III 
complex was measured dichromatically at 660/700 nm. Values representing the mean ( ± SD) of six measurements were graphed and subjected to Kruskal-Wallis test 
(p = 0.0004). Planned comparison were made between DMSO and SrcI1 treated cells and PP3 vs. PP2 treated cells using Dunnett’s test. **p  <  0.01. (C) c-Src 
inhibition and its effect on mineralization outcome of osteogenic differentiation in crt−/− mESCs assessed by von Kossa. Day 21 nodules of the indicating cells were 
stained by von Kossa method to assess the mineralized deposits under each treatment condition. representing the mean ( ± SD) of triplicates were graphed and 
subjected to one-way ANOVA. (D) Runx2 subcellular localization upon inhibition of c-Src activity. differentiating EBs from crt−/− mESCs treated with c-Src 
inhibitors (PP2 and SrcI1) and the solvent control DMSo were subjected to immunofluorescence staining using anti Runx2 antibody (Green). Confocal immuno-
fluorescence localization analysis of Runx2 trafficking in differentiating EBs from crt−/− mESCs treated with c-Src inhibitors (PP2 and SrcI1) and the solvent control 
DMSO. Dual channel grey level images of a single field are displayed with the top rows showing RUNX2 immunolocalization, PI-labelled nuclei in the middle row and 
the merged RGB images in the bottom rows. Scale bar = 50 µm. (E) Pearson’s and Manders’ coefficients should be interpreted as follows: Pearson's correlation 
coefficient returns values from + 1 to −1 with + 1 for perfect correlation (colocalization), 0 for no correlation, and −1 for total anti-correlation. Manders’ overlap 
coefficient measures positions and intensities of fluorescence of pixels in each colour channel. It returns values ranging from 1 to 0, thus showing full colocalization or 
no colocalization, respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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sensitive to differences in mean signal intensities and returns values 
from + 1 to −1 with + 1 for perfect correlation (colocalization), 0 for 
no correlation, and −1 for total anti-correlation. 
Error bars shown in the figures represent standard deviations and n 
represents the number of independent experiments performed. 
Statistical differences between two groups were analyzed by one-way or 
two-way analysis of variance or non-parametric Kruskal-Wallis test 
when appropriate using the GraphPad Prism 8.3.0 application. 
Fig. 3. Calreticulin (CRT) regulates Src kinase activity through its calcium homeostasis function. (A) c-Src activity in response to [Ca2+]i changes. WT (lane 
1), WT treated with BAPTA-AM (lane 2), crt−/− (lane 3), and crt−/− treated with ionomycin (lane 4) were western blotted using antibodies for p-Y416-c-Src and c- 
Src. GAPDH served as loading controls. (B) Representative traces of [Ca2+]i responses to c-Src inhibition in crt−/− mESCs. DMSO was the solvent control. Data 
represent the mean ( ± SD) of readings from two independent experiments. (C) Calcineurin activity comparison among cells in the absence and presence of cal-
reticulin. WT, crt−/−, crt−/− +CRT, and crt−/−+CaN mESCs were tested for level of calcineurin activity. Data represent mean  ±  SD, with significance determined 
by one-way ANOVA with a Bonferroni’s multiple comparison test. *p  <  0.05, and **p  <  0.01. (D) c-Src inhibition and its effect on calcineurin activity in crt−/− 
mESCs. crt−/− mESCs were treated with c-Src inhibitors including PP2 and SrcI1 prior to calcineurin activity measurements. Control conditions included DMSO 
(solvent Ctrl) and PP3 (inactive analog of PP2). Values representing the mean ( ± SD) of triplicates were graphed and subjected to Kruskal-Wallis test (p  <  0.0001). 
Planned comparisons were made to compare PP2 and PP3 treated cells, and SrcI1 and DMSO treated cells using Dunn’s test. **p  <  0.01. 
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Fig. 4. Calcineurin (CaN) regulates Runx2 nuclear localization downstream of Src. Runx2 subcellular localization upon inhibition of calcineurin activity. WT, crt−/ 
−, crt−/−+CaN, WT treated with cyclosporin A (CsA), and CsA treated crt−/−+CaN mESCs undergoing osteogenic differentiation were immunolabelled using anti 
Runx2 antibody. Dual channel grey level images of a single field are displayed where Runx2 staining is presented on the farthest left, PI-labelled nuclei in the middle 
column and the merged RGB images on the farthest right. Scale bar = 50 µm. For description of Pearson’s and Manders’ coefficients please see legend to Fig. 2E. 
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3. Results and discussion 
3.1. Higher c-Src activity and lower calreticulin expression were inversely 
related to osteogenic differentiation of mECs 
We have established that c-Src activity is inversely related to the 
abundance of calreticulin in mesenchymal cells (Papp et al., 2007). Here, 
we first investigated a relationship between calreticulin expression and 
osteogenic differentiation. To do so, calreticulin WT, crt−/−, and crt−/− 
transfected with calreticulin expressing vectors (crt−/−+CRT) mESCs 
were subjected to osteogenic differentiation. Cells were created and 
maintained as described previously (Papp et al., 2009; Guo, 2002; Lynch, 
2005; Mesaeli, 1999; Szabo et al., 2009). Expression of osteogenic mar-
kers and mineralization were examined from day 21 cultures by qPCR 
and von Kossa staining, respectively. The increase in osteoblast activity 
of calreticulin WT cells during differentiation was reflected in sig-
nificantly higher transcript levels of osteoblast-specific genes Runx2, Sp7 
(osterix), and Ibsp when compared to crt−/− ESCs. These reduced levels 
of osteogenic markers were rescued in crt−/−+CRT cells (Fig. 1A). In 
addition to our results in this study, we have recently shown the sup-
porting role of calreticulin in osteogenic differentiation of mouse ESCs, as 
evidenced by enhanced nuclear osterix expression in calreticulin WT 
versus crt−/− cells (Pilquil et al., 2020). The mineralization activity of 
mature osteoblasts which leads to the deposition of calcium phosphate 
was assessed by von Kossa staining (Owen, 1990; Brauer et al., 2016), in 
which Silver ions react with calcium phosphate resulting in black pre-
cipitates. Based on the staining intensity, we concluded that the level of 
mineralized deposits in crt−/− D21 nodules were compromised when 
compared to WT and crt−/−+CRT cells (Fig. 1B). 
Next, we examined c-Src kinase activity in the ESCs differentially 
expressing calreticulin based on the expression level of phosphorylated 
Src at Y416. Differentiating calreticulin WT, crt−/−, and crt−/−+CRT 
cells under osteogenic conditions were subjected to western blot ana-
lysis (Fig. 1C). Level of p-Y416-c-Src were quantified in all tested cells 
and normalized to the corresponding total c-Src, which showed that 
crt−/− cells had significantly higher levels of c-Src activity compared to 
WT cells. Furthermore, the levels of p-Y416-c-Src in crt−/−+CRT cells 
were close to those of control WT cells (Fig. 1D). The abundance of total 
c-Src remained unchanged. These results suggested that calreticulin 
plays a role in the regulation of c-Src activity in mESCs, as opposed to 
influencing total transcription levels. Furthermore, given the well-es-
tablished inhibitory role of c-Src in osteogenesis (Marzia, 2000), it is 
likely that osteogenic differentiation in crt−/− cells is impaired due to 
higher c-Src activity in these cells. 
3.2. Inhibition of c-Src activity in crt−/− ESCs improves osteogenic 
differentiation 
To investigate whether or not calreticulin mediates its effect on 
osteogenic differentiation through regulation of c-Src kinase activity, c- 
Src activity in crt−/− cells was inhibited using PP2 (10 µM) or Src-I1 
(1 µM) inhibitors. DMSO served as solvent control. RNA from D21 
nodules was extracted and subjected to qPCR analysis. The level of 
osteogenic markers, Runx2, SP7, and Ibsp, were rescued following Src 
inhibition in crt−/− cells (Fig. 2A) and so was their mineralization, as 
tested by Arsenazo III assay (Fig. 2B) and von Kossa (Fig. 2C). Arsenazo 
III assay, which revealed that Ca+2 deposits in crt−/− nodules treated 
with c-Src inhibitors were significantly higher compared to control 
dishes treated with PP3, the inactive analogue of PP2 and DMSO. This is 
in agreement with earlier observations that c-Src inhibition enhances 
osteogenic differentiation (Soriano et al., 1991; Marzia, 2000; Id 
Boufker, 2010; Lee, 2010; Murrills, 2012). Collectively, these results 
further confirmed that calreticulin affects osteogenic differentiation 
through the regulation of c-Src activity. 
Since elevated c-Src activity in crt−/− cells was shown to be linked 
to reduced osteogenic differentiation, we wished to investigate the 
subcellular distribution of Runx2 in crt−/− cells with or without c-Src 
inhibition. Immunofluorescence staining revealed Runx2 was pre-
dominantly located in the cytoplasm of non-osteogenic crt−/− cells, 
however, upon inhibition of c-Src with either PP2 (10 µM) or SrcI1 
(1 µM), the nuclear presence of Runx2 in crt−/− cells became starkly 
visible (Fig. 2D). From these results, we infer that inhibition of c-Src 
kinase in crt−/− ESCs imparts on them a capability to undergo effica-
cious osteogenic differentiation. Both Manders' overlap coefficients and 
Pearson’s correlation coefficient methods were applied to quantify co-
localization of Runx2 with propidium iodide (PI) nuclear staining and 
the summary of the outcome is provided in a table (Fig. 2E). Regulation 
of various kinase activities by calreticulin have been reported pre-
viously (Papp et al., 2008; Czarnowski et al., 2014; Szabo et al., 2007). 
We have shown that calreticulin affects c-Src activity in mouse fibro-
blasts and this is Ca2+-dependent (Papp et al., 2007). In another study, 
increased calreticulin expression was linked to lower expression of 
pERKs in rat cardiomyocytes and it was argued that calreticulin reg-
ulates ERK activity (Lee, 2003). Later, it was found that c-Src increases 
ERK activity in the rat hippocampus (Hu, 2009). However, in the ab-
sence of proper gain- and loss-of-function experiments, the direct effect 
of calreticulin on ERK activity remains unexplored. 
3.3. Calreticulin regulates Src kinase activity through its calcium 
homeostasis function 
Previously, we showed that in crt−/− mouse embryonic fibroblasts 
(MEFs), reduced ER Ca2+ concentration increased c-Src kinase activity 
(Papp et al., 2008). More recently, we showed that calreticulin reg-
ulates osteoblast specification in a Ca2+−dependent manner (Pilquil 
et al., 2020). In the current study, we asked whether or not calreticulin- 
dependent Src activity is regulated by the Ca2+ buffering function of 
calreticulin. Therefore, c-Src activity was tested in response to mod-
ification of [Ca2+] i using ionomycin (1 µM) and BAPTA-AM (100 nM). 
Western blot analysis showed that decreasing cytosolic [Ca2+] with the 
Ca+2 chelator BAPTA-AM enhanced c-Src kinase activity in WT cells 
(lane 2, Fig. 3A), while increasing cytosolic [Ca2+] with ionomycin in 
crt−/− cells reduced phosphorylation of c-Src on Y416 (lane 4, Fig. 3A). 
The abundance of total c-Src remained unchanged. To further assess the 
effect of c-Src activity on intercellular calcium, Ca2+ release in crt−/− 
cells in response to c-Src inhibition was measured using cell-permeable 
Ca2+-binding fluorescent ratiometric dye Fura-2AM to measure cyto-
solic free [Ca2+2+]. crt−/− cells showed an apparent increase in cy-
tosolic free [Ca2+] when treated with the c-Src inhibitors PP2 and SrcI1 
compared to DMSO tread cells (Fig. 3B). Increase in [Ca2+]i has been 
shown to activate many calmodulin-dependent enzymes, including 
calcineurin (Crabtree, 2001; Crabtree and SchreiberSnapShot, 2009). 
Therefore, it was critical to know how calcineurin activity was affected 
downstream of calreticulin in ES cells. Our results show that calcineurin 
activity was significantly reduced in crt−/− cells, however, calcineurin 
activity in crt−/−+CRT was restored to the WT levels. Moreover, a 
stable transfection of non-osteogenic crt−/− cells with constitutively 
active calcineurin (crt−/−+CaN) also restored calcineurin activity to 
the WT levels (Fig. 3C). Next, we asked whether or not the increase in 
cytosolic Ca2+ level following c-Src inhibition would increase calci-
neurin activity in the crt−/− cells. Interestingly, c-Src inhibition using 
either PP2 (10 µM) or SrcI1 (1 µM) inhibitors induced calcineurin ac-
tivity in crt−/− cells (Fig. 3D). These findings suggest that the in-
hibitory effect of c-Src in crt−/− cells may be directed through calci-
neurin. 
3.4. Calcineurin regulates Runx2 nuclear localization downstream of Src 
Our results indicate that calcineurin activity downstream of Src is 
reduced in crt−/− cells. We show that inhibition of Src kinase activity in 
crt−/− ES cells enhances the intranuclear translocation of Runx2. 
Osteo-chondroprogenitor cell commitment to osteoblastic cell lineage 
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during mesenchymal condensation is regulated by Runx2 (McDonnell 
et al., 1960; Porrello and LaVail, 1986). Here, we examined Runx2 
localization downstream of calcineurin in ES osteogenic differentiation. 
Runx2 was immunolocalized (Fig. 4) in cells modified with respect to 
calcineurin activity (Fig. 3C, D). Runx2 was predominantly cytoplasmic 
in crt−/− ES cells (Fig. 4; crt−/−) with lowest activity of calcineurin. 
Interestingly, with increasing calcineurin activity in WT cells and cells 
containing constitutively active calcineurin, Runx2 presence became 
increasingly intranuclear (Fig. 4; WT, and crt−/−+CaN). To confirm 
that the intranuclear translocation of Runx2 is indeed due to the cal-
cineurin activity, WT and crt−/−+CaN cells were treated with 1 µg/ml 
of the calcineurin inhibitor cyclosporin A (CsA). Immunolocalization 
microscopy revealed that upon inhibition of calcineurin activity, traf-
ficking of Runx2 to the nucleus was distinctly attenuated (Fig. 4; 
WT + CsA, and crt−/−+CaN + CsA). 
The significance of calcineurin in osteoblastic bone formation has 
been studied previously where it showed that calcineurin Aα isoform 
enhances bone formation (Sun, 2005). In another study, calcineurin/ 
NFAT signaling was found to regulate osteoblast proliferation, osteo-
clast differentiation, and the coordination of bone formation and re-
sorption (Winslow, 2006). Furthermore, inhibition of Src family kinases 
was found to enhance NFATc1 nuclear localization and activation (Baer 
et al., 2017). The authors suggested that the mechanism for increased 
NFATc1 nuclear translocation in the absence of active Src kinases could 
depend on calcineurin. Although the aforementioned work tentatively 
links calcineurin and Src activity, the potential role of calreticulin as an 
upstream regulator in osteogenesis from ESCs remains poorly char-
acterized. Our data indicate that calcineurin activity downstream of c- 
Src is likely to regulate intracellular trafficking of Runx2 and hence 
might control osteogenic differentiation from ES cells. Interestingly, 
phosphorylation of a conserved serine (S451) on Runx2 was found to 
negatively regulate Runx2 transcriptional activity (Wee et al., 2002). 
One could speculate that enhanced phosphatase activity of calcineurin 
in the presence of calreticulin and inhibition of c-Src activity might 
result in dephosphorylation of Runx2 at S451. Enhanced transcriptional 
activity of S541-dephosphorylated Runx2 could in turn enhance os-
teogenic output during ESC differentiation. 
In summary, we have shown here that the osteogenic ability of cells 
is dependent on the Ca2 + homeostatic function of calreticulin, which 
influences (reduces) c-Src activity. Downstream calcineurin activity is 
thereby also affected, such that in cells harbouring calreticulin, calci-
neurin activity is intact and Runx2, the master osteogenic transcription 
factor, is properly localized to the nucleus. The opposite scenario is true 
for calreticulin deficient cells, which have a decreased osteogenic 
ability, but which was shown to be rescued here by a variety of means, 
including c-Src inhibition and cytosolic Ca2+ increase. Thus, our re-
sults show that calreticulin is a crucial regulator in the osteogenic sig-
nalling pathway. 
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